About Ocriplasmin
Class: | Enzymatic vitreolysis agent
Use: | Treatment of symptomatic vitreomacular adhesion (VMA) including vitreomacular traction (VMT)
Adult dose: | 0.5 mg (0.2 mL) administered as a single intravitreal injection
Pediatric dose: | Safety and efficacy in pediatric patients have not been established; not recommended for use in children
Side effects: | Common side effects include blurred vision, floaters, photopsia, and retinal detachment
Contraindications: | Hypersensitivity to ocripla
Drug Class
Enzymatic vitreolysis agent
Uses & Indications
Treatment of symptomatic vitreomacular adhesion (VMA) including vitreomacular traction (VMT)
Storage Requirements
Store at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
Manufacturer & Packaging
Manufacturer: Alcon-Couvreur, BELGIUM
Package Size
0.2ml Glass Vial
Price & Supplier
Price in UAE: AED 19016.50
Dosage Information
Adult Dose
0.5 mg (0.2 mL) administered as a single intravitreal injection
Pediatric Dose
Safety and efficacy in pediatric patients have not been established; not recommended for use in children
Side Effects
Common side effects include blurred vision, floaters, photopsia, and retinal detachment
Contraindications & Precautions
Hypersensitivity to ocriplasmin or any component of the formulation; history of retinal detachment or other retinal disorders
Important Warnings
Risk of retinal detachment, vitreous hemorrhage, and other serious ocular complications; monitor patients closely after injection for signs of these complications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.